MedTrace Logo

Ribociclib in Combination With Non-steroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer

NCT05569187 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 76

Last updated 2022-11-08

No results posted yet for this study

Summary

Observational, longitudinal (retrospective cohort), multicenter, national study aiming to evaluate the proportion of women with HR+/HER2- advanced breast cancer treated with ribociclib plus non-steroidal aromatase inhibitors who were alive and without disease progression at 1 year.

Conditions

Interventions

DRUG

Ribociclib

Included patients who received doses (600 mg, 400 mg, and 200 mg) at 6 months and 1 year

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-23
Primary Completion
2021-10-29
Completion
2021-10-29

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05569187 on ClinicalTrials.gov